Tetanus immunoglobin dose and route of administration evidence
Reading File
Finding Sources
Searching PubMed
tetanus immunoglobulin dose route administration
Reading File
Reading File
Reading File
Searching PubMed
tetanus immunoglobulin intrathecal intramuscular treatment
Reading Article
PMID: 35561721
Reading Article
PMID: 16827708
Finding Sources
Finding Sources
Reading File
Finding Sources
Reading File
I now have comprehensive data from multiple authoritative sources. Let me compile the full answer.
Tetanus Immunoglobulin (TIG): Dose and Route of Administration
What TIG Does (and Its Limits)
Human TIG neutralizes circulating tetanospasmin and toxin at the wound, but cannot reverse toxin already bound to neural tissue. Even so, it may reduce mortality in clinical tetanus. A single dose is sufficient because the half-life of TIG is ~28 days - repeated doses are not needed.
1. Post-Exposure Prophylaxis (Wound Management)
| Indication | Dose | Route |
|---|---|---|
| Tetanus-prone wound, incomplete/unknown vaccination | 250 units (some sources: 500 IU) | IM (anterolateral thigh or deltoid) |
| Children | 4 units/kg | IM |
| Wound with high contamination risk | 500 units | IM, with a portion infiltrated around the wound |
- Key rule: TIG must be given at a separate site and separate syringe from tetanus toxoid (DTaP/Td/Tdap). It does not interfere with active immunization.
- Give TIG before wound debridement because toxin may be released during wound manipulation.
- Indications for TIG in wound prophylaxis (per Goldman-Cecil Medicine and Campbell's Operative Orthopaedics 2026):
| Prior tetanus toxoid doses | Clean minor wound | All other/tetanus-prone wounds |
|---|---|---|
| <3 or unknown | Toxoid: Yes / TIG: No | Toxoid: Yes / TIG: Yes |
| ≥3 doses | Toxoid: No (unless >10 yr since last) / TIG: No | Toxoid: Only if >10 yr since last / TIG: No |
2. Treatment of Clinical Tetanus
| Parameter | Recommendation |
|---|---|
| Dose | 3,000-6,000 units IM (some sources cite up to 10,000 units IV in severe cases) |
| Route | Intramuscular (standard); see intrathecal debate below |
| Site | Opposite side of body from toxoid injection; at least a portion infiltrated around the wound |
| Repeat dosing | Not required (half-life 28 days) |
- Tintinalli's Emergency Medicine: "3000 to 6000 units IM is the usual recommended dose"
- Jawetz Microbiology: "3000-10,000 units" in very severe cases
- Goldman-Cecil: "500 IU IM as soon as possible" (this lower figure is also cited and reflects some European protocols)
3. The Intrathecal Route Debate
This is the most contested area, with conflicting evidence:
2006 Meta-Analysis (Kabura et al., PMID 16827708) - favoured intrathecal:
- Pooled 12 trials, 942 patients
- Combined RR of mortality for intrathecal vs. IM = 0.71 (95% CI 0.62-0.81) - suggesting ~29% relative mortality reduction
- Benefit seen in both adults and neonates
2022 Landmark RCT (Van Hao et al., Lancet Global Health, PMID 35561721) - no benefit from intrathecal:
- 2×2 factorial RCT, 272 adults, ICU-level tetanus, Hospital for Tropical Diseases, Vietnam
- 3000 IU human IM vs. 21,000 U equine IM; ± 500 IU intrathecal human TIG
- Primary outcome (requirement for mechanical ventilation):
- Intrathecal vs. sham: RR 0.87 (95% CI 0.66-1.13; p=0.29) - no significant benefit
- Human vs. equine IM: RR 1.01 (95% CI 0.75-1.36; p=0.95) - equivalent efficacy
- Intrathecal route was safe but provided no overall advantage over IM alone
Current guideline position:
"Intrathecal administration of tetanus immunoglobulin does not appear to have advantages over standard IM delivery."
- Tintinalli's Emergency Medicine (citing the post-2006 RCT data)
The 2022 Lancet Global Health trial is the highest-quality individual trial to date and largely resolves the debate - IM remains the standard route.
4. Alternative Preparations When Human TIG Unavailable
- Equine tetanus antitoxin (ETA): 10,000-20,000 IU; higher risk of serum sickness/anaphylaxis; test dose required; shorter antibody protection than human TIG
- Pooled IV immunoglobulin (IVIG): Acceptable alternative, but titres are variable; not first-line
- Human TIG is always preferred when available
5. Special Situations
- Neonatal tetanus: TIG 500 IU IM or IV (WHO recommendation); intrathecal did not improve survival in an older RCT (Neequaye 1983, PMID 6342543)
- Pregnancy: TIG is safe; passive immunization recommended for unimmunized pregnant women with tetanus-prone wounds
- Immunocompromised patients: Standard dosing applies; active immunization may be less effective, making TIG more critical
Summary Table
| Context | Preparation | Dose | Route |
|---|---|---|---|
| Prophylaxis (tetanus-prone wound) | Human TIG | 250 units (adults); 4 u/kg (children) | IM |
| Prophylaxis (high-risk wound) | Human TIG | 500 IU | IM + infiltrate wound |
| Clinical tetanus treatment | Human TIG | 3,000-6,000 units | IM (standard) |
| No human TIG available | Equine antitoxin | 10,000-21,000 U | IM |
| Intrathecal adjunct | Human TIG | 500 IU | Intrathecal (no clear benefit per 2022 RCT) |
Sources: Tintinalli's Emergency Medicine, p. 1091; Goldman-Cecil Medicine; Campbell's Operative Orthopaedics 15th Ed 2026; Washington Manual of Medical Therapeutics; Roberts & Hedges' Clinical Procedures in Emergency Medicine; Kabura et al. 2006 meta-analysis; Van Hao et al. 2022 Lancet Global Health
Can it be given subcutaneous
Finding Sources
Searching the Web
tetanus immunoglobulin subcutaneous route administration evidence
Great - this gives a very clear and nuanced answer. Here it is:
TIG: Can It Be Given Subcutaneously?
Standard answer: No - IM is the mandated route for conventional TIG formulations.
However, the situation is more nuanced than a flat "no":
Standard IM-TIG Products
Products like HyperTET S/D and Tetanus Immunoglobulin-VF are explicitly formulated for intramuscular use only. Their datasheets state the product must not be given IV (risk of anaphylaxis), and SC is not listed as an acceptable route. The concentration and formulation of IM immunoglobulins is not suited for SC delivery - they can cause significant local tissue reactions if given SC.
The UK Exception: SC-Licensed HNIG Products
The UK Health Security Agency (UKHSA) guidance reveals an important clinical scenario where SC is used:
"Previously both intramuscular and subcutaneous routes were included in the product licence... current licence includes subcutaneous route only; however UKHSA recommends the intramuscular route."
In the UK, when standard IM-TIG is unavailable, normal human immunoglobulin (HNIG) products licensed for SC use (e.g., Subgam 16%, Cuvitru 20%, Gammanorm 16.5%) can substitute. These are given subcutaneously at equivalent anti-tetanus IU doses:
| Indication | IM-TIG dose | Subgam 16% (SC) | Cuvitru 20% (SC) |
|---|---|---|---|
| Most tetanus-prone wounds | 250 IU | 6.4 mL | 4.5 mL |
| >24 hr delay, heavy contamination, burns | 500 IU | 12.8 mL | 9 mL |
These are different product formulations (lower concentration, designed for SC delivery) - not the same product given by a different route.
Why SC Is Avoided for Standard TIG
- Slower, less predictable absorption - IM delivers antitoxin to the bloodstream faster, which matters when neutralizing circulating toxin before neural binding
- Increased local reactions - SC injection of immunoglobulins causes significantly more erythema and swelling vs. IM (confirmed in a 2022 Frontiers RCT on tetanus vaccine: SC had higher rates of erythema p=0.001 and swelling p=0.023)
- Product formulation mismatch - Standard IM-TIG has higher protein concentration not designed for SC tissue
When SC Might Be Considered
The one legitimate scenario is in patients with bleeding disorders or on anticoagulants where IM injection risks significant hematoma. In this situation:
- Use a SC-licensed HNIG product (not standard IM-TIG)
- Apply firm pressure after injection
- In the UK, this is a recognized pathway with specific dosing guidance
Bottom line: Standard TIG vials = IM only. SC is an option only if using a purpose-formulated SC immunoglobulin product, and even then IM is preferred whenever safely possible.
This is a shared conversation. Sign in to Orris to start your own chat.